Switching From Zepbound to Wegovy (and Back): An Honest Guide

A switch between Zepbound and Wegovy may be considered because of insurance, cost, availability, tolerability or treatment response. Whatever the reason, the single most important thing to understand before you switch is this: these are two different drugs, and the doses do not convert one-to-one. There is no validated "5 mg of this equals so-many milligrams of that" chart. The starting dose and timing need a prescriber's product-specific plan rather than copying the same number.

This guide walks through what the two drugs actually are, why a switch needs an individual dose plan rather than a like-for-like swap, the reasons a change may be considered, and what to realistically expect — appetite, side effects, and weight — in the weeks after. It is general health information, not medical advice; both medicines are prescription-only and any switch should be a conversation with the clinician who prescribed them.

Zepbound and Wegovy are not the same molecule

This is the foundation everything else rests on. Wegovy is semaglutide. It is a single-receptor drug: a GLP-1 receptor agonist. Zepbound is tirzepatide. It is a dual-receptor drug, acting on both the GLP-1 receptor and the GIP receptor. They are made by different companies (Wegovy by Novo Nordisk, Zepbound by Eli Lilly), approved under separate FDA labels, and titrated on completely different milligram scales.

You can see the mismatch in the numbers themselves. Per its FDA label, Wegovy injection starts at 0.25 mg weekly and normally escalates toward 2.4 mg recommended maintenance for adult weight reduction, with 1.7 mg permitted. Selected adults who tolerate 2.4 mg for at least four weeks and need further weight reduction may be prescribed 7.2 mg.⁸ Zepbound steps up through 2.5, 5, 7.5, 10, 12.5, and 15 mg⁹. The milligram figures are not comparable — a "5" on one is not a "5" on the other, because they are different chemicals at different potencies hitting different receptors. A conversion number should not be treated as permission to substitute doses independently. (If the same-molecule-different-brand idea is new to you, our explainer on Ozempic vs Wegovy shows how brand names map to molecules.)

Why the switch needs an individual dose plan

When you start either of these drugs from scratch, you don't begin at the top. You begin low and climb slowly — and that slow climb exists for a reason. Common side effects of both medicines include nausea, vomiting, diarrhea and constipation. Delayed gastric emptying is a labeled effect, but does not by itself establish the cause of every gastrointestinal symptom. The escalation schedule is the main tool clinicians use to keep those side effects tolerable, and the data back that up: in a dedicated analysis of semaglutide 2.4 mg, GI events clustered during dose escalation, were mostly mild-to-moderate and transient, and the gradual step-up was central to managing them⁷.

Tolerating a high dose of one medicine does not establish tolerance of a selected dose of the other. The labels give each product's starting and escalation instructions, but they do not supply a direct tirzepatide-to-semaglutide conversion algorithm.^8,9 A prescriber may recommend a lower starting dose or renewed escalation, taking prior treatment, interruptions and symptoms into account. It is too broad to say every switch must restart at the lowest dose, or to promise that any alternative starting point is equivalent. For the semaglutide escalation principles, see semaglutide dosing and side effects.

Ask for a written last-dose and first-dose plan, including what to do if symptoms persist. This discussion concerns the weekly injections; oral Wegovy has separate formulation-specific instructions. Do not choose the gap yourself or continue the old prescription automatically. Taking semaglutide and tirzepatide together is a separate issue: the product labels recommend against coadministration with other GLP-1 receptor agonists.^8,9

Does the switch cost you weight loss? What the head-to-head shows

This is the question most people actually care about, and here the evidence is unusually clear because the two drugs were finally compared directly. In SURMOUNT-5, a head-to-head randomized trial, tirzepatide (Zepbound) produced greater average weight loss than semaglutide (Wegovy) — roughly 20% versus about 14% of body weight over 72 weeks at the regimens tested: tirzepatide 10 or 15 mg and semaglutide 1.7 or 2.4 mg weekly.¹ It did not evaluate switching or compare tirzepatide with the newer 7.2 mg Wegovy dose. That result is consistent with the separate pivotal trials: semaglutide 2.4 mg delivered about 15% mean weight loss in STEP-1², while tirzepatide reached up to roughly 21% at its highest dose in SURMOUNT-1³.

At those tested regimens, tirzepatide produced more average weight loss. The trial does not predict how much weight an individual will lose or regain after switching, because it compared separate treatment groups rather than a switch strategy. But "on average" is doing real work in that sentence — these are population means, and individual response varies widely. Treatment response and tolerability can differ between individuals. The trial averages tell you the central tendency, not your personal outcome. For a dedicated head-to-head of the two molecules — weight loss, side effects, and cardiovascular evidence — see semaglutide vs tirzepatide: which works better?, and for the two brands' self-pay prices by dose, Wegovy vs Zepbound. For the fuller picture of what semaglutide does and doesn't do, see our pillar, how semaglutide works: results and side effects.

Cardiovascular evidence needs the population and product attached. SELECT showed cardiovascular benefit with semaglutide in adults with established cardiovascular disease and overweight or obesity without diabetes.⁴ Tirzepatide now also has published outcomes evidence: SURPASS-CVOT compared it with dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease, meeting its noninferiority criterion.¹¹ Mounjaro's current label includes major cardiovascular event reduction in high-risk adults with type 2 diabetes.¹⁰ This is not a claim that Zepbound has a SELECT-like indication for people without diabetes.

Wegovy and Ozempic heart benefits discusses the semaglutide context. For sleep apnea, Zepbound is approved to treat moderate to severe obstructive sleep apnea in adults with obesity; Wegovy does not carry that indication.⁹ If OSA is a treatment goal, include it in the switch discussion. See Wegovy and sleep apnea.

Reasons to discuss a change

Switching is rarely about chasing the "best" drug in the abstract. The real-world drivers are usually:

• •Cost and coupons. Self-pay prices, savings-card eligibility, and manufacturer offers shift over time, and a change can flip which drug is affordable this month. We track the semaglutide side in our Wegovy cost and savings guide.
• •Insurance and coverage. A formulary change, a denied prior authorization, or a new plan can suddenly cover one drug and not the other. (Our does insurance cover Wegovy or Ozempic? walks through how that plays out.)
• •Supply and shortage. Both drugs have spent time on the FDA shortage list; intermittent availability pushes people to whatever they can actually fill.
• •Tolerability. Some people simply feel less nauseated on one molecule than the other — a legitimate medical reason to switch, and one your prescriber can help you weigh.
• •Efficacy or plateau. If results stall or fall short of goals, a clinician may suggest moving to the drug with the larger average effect. A change in either direction requires its own prescribing plan.

None of these reasons is wrong. The point is just that the decision and the dose both belong with your clinician.

What to expect after you switch

An adjustment period may occur, especially if the plan includes a lower starting dose or renewed escalation. Appetite, gastrointestinal symptoms and weight can change, but neither symptoms nor a brief pause in weight loss tells you independently whether the selected dose is right. Tell the prescriber about severe or persistent symptoms rather than increasing the dose or assuming you should push through.

There is also a stopping-the-old-drug consideration baked into any switch: appetite and weight regain are real when GLP-1-class therapy is paused. In the semaglutide withdrawal trial STEP-4, people who stopped semaglutide regained a substantial share of lost weight⁵; the tirzepatide maintenance trial SURMOUNT-4 showed the same pattern — continued treatment maintained the loss, while stopping led to regain⁶. Those withdrawal studies do not establish the ideal gap for an individual switch; balance continuity with tolerability and the prescribing plan. (For what stopping looks like in general, see what happens if you stop semaglutide?.)

The bottom line

A switch is a clinician-directed change between different drugs, not a same-number swap or an invitation to overlap prescriptions. Starting dose, timing and any renewed escalation depend on the individual plan. SURMOUNT-5 compared particular regimens rather than switching outcomes; cardiovascular evidence also differs by population and product. Include cost, coverage, tolerability and the condition being treated in the decision. To compare your real options on price and oversight, see our best semaglutide providers roundup — and if tirzepatide is what you are pricing out, most of those same programs fill it too, at prices we've pulled together in best tirzepatide providers.